我国耐药肺结核病的发病率居世界之首。在临床上，对耐多药肺结核病（MDR-TB）的治疗尤为棘手。中医基于外邪感染和机体正虚辨证施治，治疗MDR-TB有较好的疗效。但中医辨证标准不统一，限制其治疗作用的提高。课题组前期采用iTRAQ-2DLC-MS/MS技术，发现非耐药肺结核病的证候标志性蛋白质GGH、IGHG3、HPT，为耐多药肺结核病的中医证候研究，奠定了实验依据。基于上述工作基础，本课题拟采用iTRAQ-2DLC-MS/MS技术筛选和鉴定MDR-TB中医证候血清特异性蛋白质，建立MDR-TB证候分型模型；并通过蛋白质功能研究，揭示差异蛋白质与MDR-TB中医证候的联系。本课题的研究结果对于中医防治耐多药肺结核病研究有重要意义，并为中医证候的生物学研究奠定科学基础。

China has the highest number of multidrug-resistant (MDR) tuberculosis (TB) patients in the world. In its MDR form, TB is more difficult to treat. The combination of Traditional Chinese medicine (TCM) and Western medicine therapy may play a certain role in treating MDR-TB. But, since there are no unified criteria for TCM syndrome classification, the therapeutic effects are limited. Previously, we have identified several specific proteins and established biomarkers, such as GGH, IGHG3, and HPT for TCM syndrome differentiation of TB by isobaric tags for relative and absolute quantitation combined with two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS). In the present study, we screened and identified specific proteins in the serum of patients with MDR-TB to establish the serum protein model for MDR-TB differentiation using iTRAQ-2DLC-MS/MS. In order to reveal the mechanism of the specific proteins, we detected the function of proteins. The present study will lay the scientific foundation for biological studies on the TCM syndrome differentiation of drug-resistant TB. The study has important significance in promoting the role of integrated TCM and Western medicine therapy against drug-resistant TB.